510(k) Summary

Page 10f-3 K002345

Surgi-Vision Urethral Coil

Common/Classification Name: Accessory to Magnetic Resonance Diagnostic Device, 21 CFR 892.1000

Surgi-Vision, Inc. 9250 Rumsey Road, Suite 100 Columbia, MD 21045

Contact: Nancy E. Taylor, Prepared: July 28, 2000

A. LEGALLY MARKETED PREDICATE DEVICES

The Surgi-Vision Urethral Coil is substantially equivalent to the Medrad MRInnervu Endorectal MRI Coils, which were cleared for marketing on June 26, 1995, in premarket notifications K952232 and K952235.

B. DEVICE DESCRIPTION

The Surgi-Vision Urethral Coil is a specialty coil for use in MRI imaging of the anatomical regions surrounding the urethra. The signals picked up by the coil are conducted through a small coaxial cable to a connection with the standard surface coil connector for GE MRI systems. The coil and cable are completely sealed inside the insulating layer.

C. INTENDED USE

The Surgi-Vision Urethral Coil is recommended for high-resolution Magnet Resonance Imaging of the female urethra. The single use, disposable Urethral Coil was designed for insertion into the urethra of the patient during MRI scans in order to obtain improved image quality in the anatomical regions surrounding the urethra. The unique coil shape facilitates orientation of the coil to the anatomy. This product is to be used with a 1.5T MRI machine.

D. SUBSTANTIAL EQUIVALENCE SUMMARY

K002345

The Surgi-Vision Urethral Coil has similar but not identical indications for use as the legally marketed predicate device. However, the intended use, providing intercavitary reception of MRI signals for the purpose of creating an MRI image of nearby anatomy, is the same.

The Surgi-Vision Urethral Coil has the same technological characteristics as the predicate device. Both proposed and predicate devices have an electronic matching circuit, a connecting coaxial cable, and an intercavitary probe with a radiofrequency receiving coil. However, there are differences in construction and design that make it necessary to provide performance data to assure substantial equivalence. Such performance data are available and do demonstrate substantial equivalence.

E. TECHNOLOGICAL CHARACTERISTICS

See Section D, above.

F. TESTING

Surgi-Vision carried out testing and/or analysis of the Surgi-Vision Urethral Coil that addressed the following issues:

- (1) Possibility of excess RF heating;
- (2) Possibility of increased susceptibility of patients to peripheral nerve stimulation;
- (3) Imaging performance; and
- (4) Mechanical testing.

The results of the heating experiments demonstrate that there is no excess heating when SVUC is positioned in a phantom that is representative of clinical conditions. The change in temperature observed during use of the SVUC is not significantly different then that observed without the coil. The calculations done to determine current leakage by the MRI pulsed gradient field demonstrate that there is no possibility of increased susceptibility of patients to nerve stimulation. Finally, the imaging performance demonstrates enhanced resolution of

K002345

urethral regions. The results of the testing demonstrate that there are no safety problems for imaging of a patient using the **Surgi-Vision Urethral Coil** if the instructions for use are followed.

The imaging performance was evaluated in a porcine model as shown in Exhibit VI. The porcine model was selected for its body mass and similarity of cutaneous and subcutaneous tissue structure. Comparison images were done using a surface coil. The SVUC images were superior to the surface coil images taken with the same imaging parameters.

Mechanical test demonstrated tensile results that exceeded the one pound minimum. These results are described in Exhibit XI.

G. CONCLUSIONS

This pre-market submission has demonstrated Substantial Equivalence as defined and understood in the Federal Food Drug and Cosmetic Act and various guidance documents issued by the Center for Devices and Radiological Health.



OCT 1 1 2000

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Nancy E. Taylor CEO/President Surgi-Vision, Inc. 9250 Rumsey Rd. Suite 100 Columbia, MD 21045 Re: K002345

Surgi-Vision Urethral Coil Dated: August 1, 2000 Received: August 2, 2000

Regulatory class: II

21 CFR 892.1000/Procode: 90 MOS

Dear Ms. Taylor:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for <u>in vitro</u> diagnostic devices), please contact the Office of Compliance at (301) 594-4639. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Daniel G. Schultz, M.D. Captain, USPHS

Acting Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

STATEMENT OF INDICATIONS FOR USE

510(K) Number (if known): <u>K002345</u>
Device name: Surgi-Vision Urethral Coil
Indications for Use:
The Surgi-Vision Urethral Coil is recommended for high-resolution Magnetic Resonance Imaging of the female urethra. The single use, disposable coil has been designed to be inserted in the urethra of the patient during MRI scans in order to obtain improved image quality in the anatomical regions surrounding the urethra. The unique coil shape facilitates orientation of the coil to the anatomy. This product is to be used with a 1.5T MRI machine.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of GDRH, Office of Device Evaluation (ODE)
Prescription Use OR Over-the-Counter Use (Per 21 CFR 801.109)
(Division Sign-Off) Division of Reproductive, Abdominal, ENT, and Radiological Devices 510(k) Number 600234